{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '117', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Table 10 Analysis Strategy for Safety Parameters', '95% CI for', 'Safety', 'Treatment', 'Descriptive', 'Tier', 'Safety Endpoint', 'Comparison', 'Statistics', 'Any AE (10% of participants in one of the treatment groups)', 'X', 'X', 'Any Grade 3 to 5 AE (5% of participants in one of the', 'X', 'X', 'Tier 2', 'treatment groups)', 'Any serious AE (5% of participants in one of the treatment', 'X', 'X', 'groups)', 'Any AE', 'X', 'Tier 3', 'Change from baseline results (laboratory test toxicity grade)', 'X', 'Abbreviations: AE = adverse event; CI = confidence interval; X = results will be provided.', '9.6.3', 'Statistical Methods for Patient-reported Outcome Analyses', 'Mean change from baseline', 'The time point for the mean change from baseline will be determined based on blinded data', 'review prior to the database lock for any PRO analysis and documented in the sSAP.', 'To assess the treatment effects on the PRO score change from baseline in the PRO endpoints', 'defined in Section 9.4.3, a constrained longitudinal data analysis (cLDA) model proposed by', 'Liang and Zeger [Liang, Kung-Yee and Zeger, Scott L. 2000 will be applied, with the PRO', 'score as the response variable, and treatment, time, the treatment by time interaction, and', 'stratification factors used for randomization (See Section 6.3.2) as covariates. The treatment', 'difference in terms of least square (LS) mean change from baseline will be estimated from', 'this model together with 95% CI. Model-based LS mean with 95% CI will be provided by', 'treatment group for PRO scores at baseline and postbaseline time point.', 'Time to Deterioration (TTD)', 'For the TTD endpoints defined in Section 9.4.3, the Kaplan-Meier method will be used to', 'estimate the TTD curve for each treatment group. The estimate of median time to', 'deterioration and its 95% CI will be obtained from the Kaplan-Meier estimates. The', 'treatment difference in TTD will be assessed by the stratified log-rank test. A stratified Cox', \"proportional hazard model with Efron's method of tie handling and with a single treatment\", 'covariate will be used to assess the magnitude of the treatment difference (ie, HR). The HR', 'and its 95% CI will be reported. The same stratification factors used for the stratified PFS', 'and os analyses will be used as the stratification factors in both the stratified log-rank test', 'and the stratified Cox model.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '118', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '9.6.4', 'Demographic and Baseline Characteristics', 'The comparability of the treatment groups for each relevant demographic and baseline', 'characteristic will be assessed by the use of tables and/or graphs. No statistical hypothesis', 'tests will be performed on these characteristics. The number and percentage of participants', 'screened and randomized and the primary reason for screening failure and discontinuation', 'will be displayed. Demographic variables, baseline characteristics, primary and secondary', 'diagnoses, and prior and concomitant therapies will be summarized by treatment, either by', 'descriptive statistics or categorical tables.', '9.7', 'Interim Analyses', 'NOTE: As of Amendment 007-06, no interim analyses of the study will be performed.', 'This section is no longer applicable.', '9.7.1', 'Safety Interim Analyses', 'The DMC conducted regular safety monitoring. The timing of the safety monitoring was', 'specified in the DMC charter. No further analysis is warranted.', '9.8', 'Multiplicity', 'NOTE: As of Amendment 007-06, no interim or final analyses of the study will be', 'performed. This section is no longer applicable.', '9.9', 'Sample Size and Power Calculations', 'NOTE: As of Amendment 007-06, no interim or final analyses of the study will be', 'performed. This section is retained for reference.', 'The study will randomize 620 participants in a 1:1 ratio into the pembrolizumab + lenvatinib', 'and pembrolizumab + placebo arms. PFS and os are primary endpoints for the study, with', 'OR as the secondary endpoint.', 'For the PFS endpoint, based on a target number of 416 events at the final PFS analysis, the', 'study has approximately 86.5% power to detect an HR of 0.7 at the initially allocated', 'a=0.0055 (1-sided).', 'For the OS endpoint, based on a target number of 388 events and one interim analysis at', 'approximately 78% of the target number of events, the study has approximately 90% power', 'to detect an HR of 0.71 at the initially allocated x=0.0195 (1-sided).', 'Based on KEYNOTE-042 data, the above sample size and power calculations for PFS and', 'OS assume the following:', 'PFS follows a piecewise exponential distribution, with a median of 5 months up to 6.5', 'months and then a median of 12 months thereafter for the control group.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}